908 Devices (NASDAQ:MASS) Posts Earnings Results, Beats Estimates By $0.04 EPS

908 Devices (NASDAQ:MASS) announced its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04, FiscalAI reports. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.54%. The firm had revenue of $18.95 million during the quarter, compared to analysts’ expectations of $18.31 million.

Here are the key takeaways from 908 Devices’ conference call:

• Revenue growth accelerated and guidance increased: Q3 revenue rose 35% year over year to a record $19 million, and the company raised the low end of its 2026 revenue outlook to $68.5 million–$70 million, implying 22%–25% annual growth.
• Device adoption broadened, including internationally: 908 Devices shipped a record 300-plus devices, bringing its installed base to about 4,400; international customers accounted for 40% of Q3 revenue, supported by ProtectIR government wins and other platform demand.
• NIRLab showed early commercial traction: The company sold about 100 devices in the quarter, while platform scans surpassed 1 million cumulatively. Management sees subscriptions and broader connected services as a potential source of recurring revenue, though the business is still developing.
• Profitability improved modestly, while future growth depends on execution: Adjusted EBITDA loss was $1.7 million, and the company ended Q3 with $99.1 million in cash and no debt. Management cited the next-generation MX908 and potential 2027 AVCAD orders as growth drivers, but AVCAD revenue is excluded from 2026 guidance and reaching the upper end of the outlook depends on closing key Q4 opportunities.

908 Devices Trading Down 14.2%

Shares of MASS stock traded down $1.63 on Tuesday, reaching $9.88. 213,061 shares of the stock were exchanged, compared to its average volume of 337,247. The business’s 50 day moving average price is $11.21 and its 200 day moving average price is $8.50. The company has a market capitalization of $408.38 million, a price-to-earnings ratio of -10.40 and a beta of 0.66. 908 Devices has a twelve month low of $5.03 and a twelve month high of $13.35.

Analyst Ratings Changes

MASS has been the topic of a number of research reports. Stifel Nicolaus increased their target price on shares of 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a research note on Wednesday, November 4th. Roth Capital upped their price objective on 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Canaccord Genuity Group began coverage on 908 Devices in a research note on Thursday, September 10th. They issued a “buy” rating and a $13.50 price objective on the stock. Finally, Wall Street Zen cut 908 Devices from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.83.

Insider Activity at 908 Devices

In other news, SVP John Kenneweg sold 21,399 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $10.11, for a total value of $216,343.89. Following the transaction, the senior vice president owned 57,784 shares in the company, valued at approximately $584,196.24. This represents a 27.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Joseph H. Iv Griffith sold 11,459 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $10.95, for a total value of $125,476.05. Following the completion of the transaction, the chief financial officer owned 121,497 shares in the company, valued at approximately $1,330,392.15. The trade was a 8.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 134,115 shares of company stock valued at $1,473,296 over the last quarter. 28.20% of the stock is owned by insiders.

About 908 Devices

908 Devices Inc is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions.

The company’s product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.